Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Toshiya Moriwaki"'
Autor:
Sho Sato, Andy Sykes, Stuart Stafford, Yoshihiko Tagawa, Rosa Fradley, Shyam Bechar, Eimear Howley, Tomoki Yoneyama, Toshal Patel, Toshiya Moriwaki, Satoru Asahi
Publikováno v:
Pharmaceutical Research
Purpose TAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::555d0fce1c6fb48f63df6e77a80c4bce
https://doi.org/10.1007/s11095-020-02893-x
https://doi.org/10.1007/s11095-020-02893-x
Autor:
Tamara J. van Steeg, Akihiko Goto, Takeshi Wakabayashi, Toshiya Moriwaki, Yoshihiko Tagawa, Joost DeJongh, Yoshiyuki Furukawa, Sho Sato, Tetsuya Tsukamoto, Yuu Moriya, Satoru Asahi
Publikováno v:
Biopharmaceutics & Drug Disposition. 38:373-380
In a dog toxicokinetic study, an unusual plasma concentration increase of the highly lipophilic compound TAK-357 was observed 2 weeks after termination of a 2-week repeated dosing in one dog with acute body weight loss. The present study investigates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a90f3087305bb61caebee11bb7ec6ee8
https://doi.org/10.1002/bdd.2075
https://doi.org/10.1002/bdd.2075
Publikováno v:
Pharmaceutical research. 35(10)
This study was designed to investigate the effects of P-glycoprotein (P-gp) expressed in the intestine on the nonlinear pharmacokinetics (PK) of T-3256336, an inhibitor of apoptosis protein inhibitor, and food effects on its bioavailability in rats.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f14d048c69cdbccafa3b295e05251342
https://pubmed.ncbi.nlm.nih.gov/30105478
https://pubmed.ncbi.nlm.nih.gov/30105478
Autor:
Yasushi Fujioka, Teruaki Okuda, Hideki Hirabayashi, Yohei Kosugi, Toshiya Moriwaki, Tomoko Igari
Publikováno v:
Xenobiotica. 44:336-344
1. This study optimized the reported approach for the prediction of drug-drug interactions (DDIs) using hepatocytes suspended in serum (HHSS) and provided a practical usage of HHSS in the early and late phases of drug discovery. 2. First, the IC50 wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8f9b9178127e319899ef52c2687cdd8
https://doi.org/10.3109/00498254.2013.837988
https://doi.org/10.3109/00498254.2013.837988
Publikováno v:
Drug Metabolism and Disposition. 41:683-688
To date, the in vitro-in vivo correlation (IVIVC) of P-glycoprotein (P-gp)-mediated drug-drug interaction (DDI) at the blood-brain barrier (BBB) in rats indicated that the cutoff value to significantly affect the brain penetration of digoxin was [I,u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d64e8bf41313eddacbd6cbbb1f6bddd
https://doi.org/10.1124/dmd.112.049577
https://doi.org/10.1124/dmd.112.049577
Autor:
Hitomi Yamasaki, Naohiro Kawaguchi, Junzo Takahashi, Satoru Asahi, Hideki Hirabayashi, Akio Morohashi, Masami Nonaka, Toshiya Moriwaki
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 47(12)
1. TAK-438, vonoprazan fumarate, is a novel orally active potassium-competitive acid blocker, developed as an antisecretory drug. In this study, we investigated the in vitro metabolism of 14C-labeled TAK-438. In human hepatocytes, M-I, M-II, M-III an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f1a6e4602c43e51a2d900ef9578e053
https://pubmed.ncbi.nlm.nih.gov/27414183
https://pubmed.ncbi.nlm.nih.gov/27414183
Autor:
Takahiro Kondo, Akio Morohashi, Ai Bernards, Satoru Asahi, Toshiya Moriwaki, Naohiro Kawaguchi, Masami Nonaka, Toshiyuki Takeuchi, Akifumi Kogame, Yoshihiko Tagawa, Hitomi Yamasaki
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 47(3)
1. Following oral administration of [14C]TAK-438, the radioactivity was rapidly absorbed in rats and dogs. The apparent absorption of the radioactivity was high in both species.2. After oral administration of [14C]TAK-438 to rats, the radioactivity i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23b2ee292b96902309d9bbe3cac6a36
https://pubmed.ncbi.nlm.nih.gov/27225050
https://pubmed.ncbi.nlm.nih.gov/27225050
Autor:
Satoru Asahi, Takuya Ebihara, Yoshihiko Tagawa, Yuu Moriya, Takahiro Kondo, Toshiyuki Takeuchi, Toshiya Moriwaki
Publikováno v:
Drug research. 66(6)
TAK-475 (lapaquistat acetate) is a squalene synthase inhibitor and M-I is a pharmacologically active metabolite of TAK-475. Preclinical pharmacokinetic studies have demonstrated that most of the dosed TAK-475 was hydrolyzed to M-I during the absorpti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ac747c175b1454b753ea3b44ad7f1c8
https://pubmed.ncbi.nlm.nih.gov/27011383
https://pubmed.ncbi.nlm.nih.gov/27011383
Publikováno v:
Drug research. 66(6)
The pharmacokinetics of TAK-475 (lapaquistat acetate), a squalene synthase inhibitor, was investigated in rats and dogs. After oral administration of (14)C-labeled TAK-475 ([(14)C]TAK-475) to rats and dogs at a dose of 10 mg/kg, the bioavailability (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfe2600391b697fd6d9d59027c9ab6d9
https://pubmed.ncbi.nlm.nih.gov/26839207
https://pubmed.ncbi.nlm.nih.gov/26839207
Autor:
Muneto Mogi, Yuka Ikegami, Klaus Urbahns, Masaomi Tajimi, Takeshi Yura, Marumo Makiko, David Madge, Noriyuki Yamamoto, Kayo Yasoshima, Tsutomu Masuda, Jang Bahadur Gupta, Nagahiro Yoshida, Fiona Chan, Hiroshi Fujishima, Toshiya Moriwaki
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:3408-3411
Starting from a naphthol-based lead series with low oral bioavailability, we have identified potent TRPV1 antagonists with oral bioavailability in rats. These compounds emerged from SAR studies aimed at replacing the lead's phenol structure whilst ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb33921a125c30096403ba92dfcdaac9
https://doi.org/10.1016/j.bmcl.2012.03.108
https://doi.org/10.1016/j.bmcl.2012.03.108